Traditional clinical trial designs were dependent upon subject visits to a healthcare or research facility for assessment. Decentralized clinical trials (DCTs) minimize such in-clinic visits through the use of telemedicine, electronic tools, remote assessment and wearable devices to collect data. One way to conceptualize this is that traditional study designs demanded that patients participated in clinical trials by going to clinics, while DCTs enable the “clinic” to go to the patients. The advantages of DCTs, enabled by currently available technologies, are substantial. We are now able to meet the patients where they are, in naturalistic settings, minimizing the burden of study participation. Former concerns about data integrity have been replaced by an awareness that high quality data can be collected remotely, and in greater volume, than ever before possible in traditional study designs. Not only are we able to meet the patients where they are, we also can now meet the physician investigators where they are, given that telemedicine has gained widespread use.
Clinilabs conducts DCTs using “best in class” technology tools from our in-house data systems and from 3rd party vendors. We are differentiated from other CROs in that we are experts in identifying the right tools for the right jobs, and we are able to ensure interoperability of data systems. Such full integration creates a bundled value when conducting DCTs.
I must say, I spend a lot of my time these days trying to persuade people that controlled trials are the only way to get information that’s reliable about drugs.
– Louis Lasagna